Since Provention Bio Inc. (NASDAQ:PRVB) and InflaRx N.V. (NASDAQ:IFRX) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the analyst recommendations, profitability, risk, dividends, earnings and valuation, institutional ownership of both companies.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Provention Bio Inc.	N/A	0.00	26.75M	-0.74	0.00
InflaRx N.V.	N/A	0.00	N/A	-1.42	0.00

We can see in table 1 the earnings per share (EPS), top-line revenue and valuation of Provention Bio Inc. and InflaRx N.V.

Profitability

Table 2 has Provention Bio Inc. and InflaRx N.V.’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
Provention Bio Inc.	0.00%	0%	0%
InflaRx N.V.	0.00%	-22.7%	-21.9%

Liquidity

53.7 and 53.7 are the respective Current Ratio and a Quick Ratio of Provention Bio Inc. Its rival InflaRx N.V.’s Current and Quick Ratios are 18.7 and 18.7 respectively. Provention Bio Inc. has a better chance of clearing its pay short and long-term debts than InflaRx N.V.

Analyst Ratings

The table delivered features the ratings and recommendations for Provention Bio Inc. and InflaRx N.V.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Provention Bio Inc.	0	0	0	0.00
InflaRx N.V.	0	0	1	3.00

Competitively the consensus price target of InflaRx N.V. is $58, which is potential 14.67% upside.

Insider and Institutional Ownership

Roughly 6.1% of Provention Bio Inc. shares are owned by institutional investors while 58.4% of InflaRx N.V. are owned by institutional investors. About 13.9% of Provention Bio Inc.’s share are owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Provention Bio Inc.	-2.72%	-1.96%	0.81%	-34.9%	0%	41.24%
InflaRx N.V.	16.4%	16.44%	25.22%	14.31%	39.39%	4.98%

For the past year Provention Bio Inc.’s stock price has bigger growth than InflaRx N.V.

Summary

On 5 of the 7 factors Provention Bio Inc. beats InflaRx N.V.

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D. The company was incorporated in 2016 and is based in Oldwick, New Jersey.

InflaRx GmbH, a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology in the United States. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company is involved developing IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and other chronic/autoimmune diseases, as well as IFX-2 for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. The company was founded in 2007 and is headquartered in Jena, Germany.